Jaguar Health, Inc. (JAGX) financial statements (2021 and earlier)

Company profile

Business Address 201 MISSION STREET, SUITE 2375
SAN FRANCISCO, CA 94105
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 3118
Cash and cash equivalents 3118
Restricted cash and investments  01 
Receivables 1000
Inventory, net of allowances, customer advances and progress billings 3200
Inventory 3200
Prepaid expense   00
Deferred costs   00
Other undisclosed current assets 10  
Total current assets: 8438
Noncurrent Assets
Property, plant and equipment 1111
Intangible assets, net (including goodwill) 3239  
Goodwill  5  
Intangible assets, net (excluding goodwill) 3233  
Restricted cash and investments    3
Other undisclosed noncurrent assets 0 00
Total noncurrent assets: 334014
TOTAL ASSETS: 4144412
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 101011
Accounts payable 5711
Accrued liabilities 5211
Debt 5222
Deferred compensation liability  0  
Deferred revenue and credits000
Other undisclosed current liabilities 11411
Total current liabilities: 271544
Noncurrent Liabilities
Long-term debt and lease obligation  1124
Long-term debt, excluding current maturities  1124
Liabilities, other than long-term debt   00
Deferred revenue and credits 00
Total noncurrent liabilities:  1124
Total liabilities: 272668
Temporary equity, carrying amount 9   
Stockholders' equity
Stockholders' equity attributable to parent, including: 517(2)4
Common stock   00
Additional paid in capital 100803830
Accumulated deficit (95)(62)(40)(26)
Other undisclosed stockholders' equity attributable to parent 00  
Total stockholders' equity: 517(2)4
TOTAL LIABILITIES AND EQUITY: 4144412

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 4400
Revenue, net100
Cost of revenue (3)(1)(0)(0)
Gross profit: 2300
Operating expenses (35)(39)(14)(13)
Other undisclosed operating income 3100
Operating loss: (31)(34)(14)(12)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 00(0)(0)
Interest and debt expense (3)(2)(1)(3)
Loss from continuing operations before equity method investments, income taxes: (34)(36)(15)(16)
Other undisclosed income from continuing operations before income taxes 21  
Loss from continuing operations before income taxes: (32)(35)(15)(16)
Income tax expense (benefit)  13(6)(5)
Loss before gain (loss) on sale of properties: (32)(22)(20)(21)
Other undisclosed net income   64
Net loss attributable to parent: (32)(22)(15)(16)
Preferred stock dividends and other adjustments (1)  (0)
Other undisclosed net income available to common stockholders, basic 1   
Net loss available to common stockholders, diluted: (32)(22)(15)(17)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (32)(22)(15)(16)
Comprehensive loss, net of tax, attributable to parent: (32)(22)(15)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: